HCG Manavata Cancer Centre (HCGMCC), Nashik, has entered into a strategic partnership with health-tech company Qure.ai to accelerate the adoption of artificial intelligence in early lung disease detection. The collaboration aims to make precision diagnostics more accessible in tier-2 and tier-3 cities of India, where late detection remains a major challenge in managing lung cancer and other respiratory illnesses.

As part of this initiative, HCGMCC will integrate qXR (AI-powered chest X-ray), qCT (AI-enabled chest CT), and qTrack (disease management platform) into its diagnostic ecosystem. These technologies enable real-time identification of high-risk findings, automated triaging, and structured follow-up, thereby reducing delays in diagnosis and improving patient outcomes.

The program is aligned with Qure.ai’s ongoing collaboration with Johnson & Johnson MedTech, which focuses on scaling AI-driven lung health solutions nationwide.

“A 5 mm nodule missed today can become stage-four cancer tomorrow. With Qure.ai’s AI tools acting as a constant digital sentinel, we can detect abnormalities before they escalate. This partnership expands the frontiers of early detection and timely intervention,” said Prof. Dr. Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director, KIMS Manavata Hospitals, HCG Manavata Cancer Centre & Six Sigma, Nashik.

Adding to this momentum, HCGMCC has also introduced a dedicated Incidental Pulmonary Nodule (IPN) Clinic, designed as part of a hub-and-spoke care model for the region. This clinic will ensure structured monitoring of suspicious nodules and facilitate timely clinical decisions, particularly critical for early-stage lung cancer cases.

“This alliance is more than just about technology—it’s about building a future-ready oncology ecosystem where AI, robotics, and advanced therapies converge to serve patients even beyond metros,” Dr. Nagarkar added.

HCGMCC has been at the forefront of oncology innovation. Over the past year, the centre has:

• Developed a blood test capable of detecting 30 different cancers with 98.4% accuracy, published in Cancer Reports.
  
• Established a Centre of Excellence in Cell and Gene Therapy, offering next-generation treatments like CAR-T cell therapy to patients in regional India.

Highlighting the institution’s vision, Dr. Nagarkar emphasised: “Our goal is to make advanced cancer care accessible everywhere, not just in urban hubs. From AI-powered imaging to robotic precision surgeries and cell therapies, we are bringing tomorrow’s oncology to patients today.”

Also read: Gujarat Health Minister Unveils State-of-the-Art Radiotherapy System at Apollo Hospitals, Ahmedabad

With this partnership, HCGMCC positions itself as a pioneering oncology hub in India’s heartland, advancing the integration of AI and next-gen therapies to deliver equitable, world-class cancer care.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!